Aspira Women's Health up on distribution deal for cancer detection tests
05/10/2022 14:05
** Shares of Aspira Women's Health Inc AWH.O up 6.84% at
$0.42 premarket
** In co-marketing and distribution pact with BioReference
for Ova1Plus, a test to detect risk of ovarian malignancy in
women urn:newsml:reuters.com:*:nGNX2MkFtm
** Under terms, AWH and BioReference will collaborate to
sell Ova1Plus to gynecologists and other women's healthcare
providers nationwide
** Up to Tuesday's close, stock had fallen ~78% YTD
(Reporting by Khushi Mandowara)
((Khushi.Mandowara@thomsonreuters.com;))
Recent news on Aspira Women's Health
See all newsBrief: Aspira Women’S Health Announces Receipt Of Delisting Notification From Nasdaq
Brief: Aspira Women's Health On April 4, Enters Equity Purchase Agreement With Triton Funds
Brief: Aspira Women's Health Files For Offering Up To 50 Units, 50 Mln Pre-Funded Units
Brief: Aspira Women's Health Interim CFO John Kallassy Resigns
Brief: Aspira Women's Health Fails To Regain Nasdaq Compliance